国人恶性胶质瘤细胞系的蛋白质组差异表达分析
|
摘要
背景：胶质瘤是最常见的颅内恶性肿瘤,病情进展快,早期多无明显临床表现,大部分患者就诊时已是中晚期,由于本身具有侵袭性生长的特性,与正常脑组织无明显界限,多数不限于一个脑叶,手术常无法全切,即使辅助以放、化疗,其疗效仍较差,复发率和死亡率仍较高,严重危害人类健康。早期发现和鉴别胶质瘤对胶质瘤的治疗意义重大。随着影像学的发展,胶质瘤的临床诊断取得了长足的进步,但是胶质瘤的生物学诊断仍缺乏有效的手段,造成这一现状的主要原因是胶质瘤缺乏敏感的、特异的生物学标志物。近年来蛋白组学的飞速发展,给寻找新的脑胶质瘤标志物提供了新的技术平台。而早期诊断与鉴别有赖于对胶质瘤标本、血浆、脑脊液中特异肿瘤生物学标志物的发现。胶质瘤血清蛋白表达谱的研究国内外很少,可能是由于血-脑屏障导致胶质瘤特异性蛋白在血清表达中很少。脑胶质瘤细胞的代谢产物可直接进入脑脊液,因此脑脊液中蛋白质的特异性改变可动态反映脑胶质瘤的代谢状态,因此对脑脊液中蛋白质组分进行分析可能找到胶质瘤特征性生物标志物。然而胶质瘤生物学标记研究中应用最多的还是对肿瘤标本或细胞系进行分析,以寻找与肿瘤诊断、良恶性区分的肿瘤标志物。本文对恶性胶质瘤细胞系进行蛋白质组学研究,希望尽可能多地寻找到参与国人胶质瘤恶性演变的特异蛋白质,将有助于进一步阐明胶质瘤发病机理、寻找治疗靶点、进行临床用药筛选和新药物的研发。
目的：建立国人恶性胶质瘤细胞系的蛋白质组差异表达谱,为以其为基础的相关研究提供必要参考。尽可能多地寻找到参与国人胶质瘤恶性演变的关键蛋白质,对于阐明胶质瘤发病机理、寻找治疗靶点、进行临床用药筛选和新药物研发等提供理论依据和数据参考。
方法：提取3例国人恶性胶质瘤细胞系CHG-5、TJ899和TJ905的总蛋白,等比例混匀后行双向电泳,正常胶质细胞为平行对照,筛选和鉴定出差异蛋白质点,并就其中部分蛋白质进行细胞免疫化学方法验证。
结果：共筛选出13个差异蛋白质点,5个蛋白表达下降,8个表达水平上升,其中10个得到成功鉴定,它们主要分属于细胞骨架蛋白、代谢相关蛋白、肿瘤细胞迁移,以及应激与炎症反应相关蛋白。细胞免疫化学检测结果与蛋白质组技术结果相似。
结论：国人恶性胶质瘤细胞系与正常胶质细胞比较具有明显的多个差异蛋白表达,它们可能共同参与脑胶质细胞的瘤变过程。
Background: Glioma is the most commonest intracranial malignant tumor. Glioma cells proliferate rapidly.lt has no obvious clinical symptoms in early stage. So many patients seek medical treatment till late stage.Because of its character of invasive growth, no obvious boundaries between normal brain tissues, the majority is not limited to one brain lobe, surgery often can not totally resect tumor tissues, even if combining radiotherapy and chemotherapy, its clinical effect is still poor, the recurrence rate and mortality is still high,it seriously endanger human health. Early detection and identification of glioma has great significance for glioma therapy. With the development of imaging, clinical diagnosis of glioma has made considerable progress, but the biological diagnosis of glioma is still lack of effective means, resulting in this situation is mainly due to lack of sensitive, specific biological markers. Proteomics has developed rapidly in recent years, and it will provide a new technology platform for finding many new tumor biological markers. And early diagnosis and identification depend on specific tumor biomarker discoveries of glioma specimens, plasma, cerebrospinal fluid. Human serum protein expression profiling study is rare at home and abroad, may be due to the blood-brain barrier leading to specific tumor protein expression in serum is very slow.Glioma cell metabolites secrete directly into the cerebrospinal fluid, so the specific protein in cerebrospinal fluid reflect glioma metabolism changes dynamically, the protein component analysis of cerebrospinal fluid may find a specific tumor markers. However glioma biomarker research is still most wide using tumor specimens or cell lines for analysis to find tumor markers for diagnosis, distinguishing benign or malignant tumor.We conducted proteomics research on malignant glioma cell lines in order to find much more specific proteins which participate in the malignant evolution of glioma, it will be helpful to further elucidating the pathogenesis, looking for therapeutic targets, screening clinical drug and developing new drugs.
Objective:To establish the differential proteomics expression profiles of malignant glioma cell lines from Chinese, and provide reference for other basic related researches. To find key proteins as much as possible which participate in the malignant evolution of glioma from Chinese, and provide theoretical basis and reference data for elucidating the pathogenesis of gliomas, looking for therapeutic targets, screening clinical drugs and developing new drugs.
Methods: The total protein was extracted from 3 gliobma cell lines, named CHG-5, TJ899 and TJ905. After an even mixing, the total protein was presented by two-dimensional (2D) electrophoresis, scanned and analyzed. Part of the identified protein spots were verified by immunocytochemistry. The glia cells were used as control through the study.
Results:13 differential protein spots were selected,5 protein expression level decreased, eight protein expression level increased,and 10 protein spots were identified successfully, which probably involved in cytoskeleton forming, cellular metabolism, tumor migration, stress and inflammatory reaction. These results were coincident with that from immunocytochemistry.
Conclusion:There were obviously differential proteomics expression between glioma cell lines and normal glia cells, and they may play key roles in the transform progress of glia to glioma.
目的：建立国人恶性胶质瘤细胞系的蛋白质组差异表达谱,为以其为基础的相关研究提供必要参考。尽可能多地寻找到参与国人胶质瘤恶性演变的关键蛋白质,对于阐明胶质瘤发病机理、寻找治疗靶点、进行临床用药筛选和新药物研发等提供理论依据和数据参考。
方法：提取3例国人恶性胶质瘤细胞系CHG-5、TJ899和TJ905的总蛋白,等比例混匀后行双向电泳,正常胶质细胞为平行对照,筛选和鉴定出差异蛋白质点,并就其中部分蛋白质进行细胞免疫化学方法验证。
结果：共筛选出13个差异蛋白质点,5个蛋白表达下降,8个表达水平上升,其中10个得到成功鉴定,它们主要分属于细胞骨架蛋白、代谢相关蛋白、肿瘤细胞迁移,以及应激与炎症反应相关蛋白。细胞免疫化学检测结果与蛋白质组技术结果相似。
结论：国人恶性胶质瘤细胞系与正常胶质细胞比较具有明显的多个差异蛋白表达,它们可能共同参与脑胶质细胞的瘤变过程。
Background: Glioma is the most commonest intracranial malignant tumor. Glioma cells proliferate rapidly.lt has no obvious clinical symptoms in early stage. So many patients seek medical treatment till late stage.Because of its character of invasive growth, no obvious boundaries between normal brain tissues, the majority is not limited to one brain lobe, surgery often can not totally resect tumor tissues, even if combining radiotherapy and chemotherapy, its clinical effect is still poor, the recurrence rate and mortality is still high,it seriously endanger human health. Early detection and identification of glioma has great significance for glioma therapy. With the development of imaging, clinical diagnosis of glioma has made considerable progress, but the biological diagnosis of glioma is still lack of effective means, resulting in this situation is mainly due to lack of sensitive, specific biological markers. Proteomics has developed rapidly in recent years, and it will provide a new technology platform for finding many new tumor biological markers. And early diagnosis and identification depend on specific tumor biomarker discoveries of glioma specimens, plasma, cerebrospinal fluid. Human serum protein expression profiling study is rare at home and abroad, may be due to the blood-brain barrier leading to specific tumor protein expression in serum is very slow.Glioma cell metabolites secrete directly into the cerebrospinal fluid, so the specific protein in cerebrospinal fluid reflect glioma metabolism changes dynamically, the protein component analysis of cerebrospinal fluid may find a specific tumor markers. However glioma biomarker research is still most wide using tumor specimens or cell lines for analysis to find tumor markers for diagnosis, distinguishing benign or malignant tumor.We conducted proteomics research on malignant glioma cell lines in order to find much more specific proteins which participate in the malignant evolution of glioma, it will be helpful to further elucidating the pathogenesis, looking for therapeutic targets, screening clinical drug and developing new drugs.
Objective:To establish the differential proteomics expression profiles of malignant glioma cell lines from Chinese, and provide reference for other basic related researches. To find key proteins as much as possible which participate in the malignant evolution of glioma from Chinese, and provide theoretical basis and reference data for elucidating the pathogenesis of gliomas, looking for therapeutic targets, screening clinical drugs and developing new drugs.
Methods: The total protein was extracted from 3 gliobma cell lines, named CHG-5, TJ899 and TJ905. After an even mixing, the total protein was presented by two-dimensional (2D) electrophoresis, scanned and analyzed. Part of the identified protein spots were verified by immunocytochemistry. The glia cells were used as control through the study.
Results:13 differential protein spots were selected,5 protein expression level decreased, eight protein expression level increased,and 10 protein spots were identified successfully, which probably involved in cytoskeleton forming, cellular metabolism, tumor migration, stress and inflammatory reaction. These results were coincident with that from immunocytochemistry.
Conclusion:There were obviously differential proteomics expression between glioma cell lines and normal glia cells, and they may play key roles in the transform progress of glia to glioma.
引文
[1]Pandey A,Mann M:Proteomics to study genes and genomics.Nature 2003,422:837-846.
[2]Washinger C V,Cord well S J, Cerpa-poljak A,et al.Progress with gene-product mapping of the Mollicutes:Mycoplasma genitalium[J], Electrophoresis,1995,16 (7):1090-1094.
[3]Abbott A:Apost-genomic challenge:learning to read patterns of protein synthesis. Nature 1999,402:715-720.
[4]Fields S,Proteomics on genomeland.Science,2001,291(5507):1221-1224.
[5]Patterson S D, Aebersold R H. Proteomies:the first decade and beyond. Nat Gen-et,2003,(Supp1):311-323.
[6]Gorg A,Obermaier C,Boguth G,et al.The current state of two-dimensional electrop-horesis with immobilized pH gradients.Electrophoresis,2000,21:1037-1053.
[7]O,Farrell PH.High resolution two-dimensional electrophoresis of protein [J]. J Boil Chem,1975,250(10):4007-4021.
[8]Thongboonkerd V. Proteomics.Forum Nutr,2007,60:80-90.
[9]Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophore-sis and mass spectrometry:Strengths and limitations.Trac-Trends Anal Chem,200 3,5:273-281.
[10]王忠诚.王忠诚神经外科学[M].湖北科技出版社,2005：212-218.
[11]Bicknese A R,Goodwin H S, Quinn C O, et al.Human umbilica cord blood cells can be induced to express markers for neurons and glia.Cell Transplant,2002,11: 261-264.
[12]Odreman F,Vindigni M,Gonzales M L,et al.Proteomic studies on low-and high-grade human brain astrocytomas[J].J Proteome Res,2005,4(3):698-708.
[13]Mennel HD, Hallier-Neelsen M, Hagner S, et al. Two novel cell specific recept-or proteins,CRLR and CD117 in human glial tumors [J].Clin Neuropathol,2006, 25(3):107-114.
[14]Zheng P P,Luider T M, Pieters R,et al.Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain turn- ors[J].J Neuropathol Exp Neurol,2003,62(8):855-862.
[15]Khwaja F W,Reed M S,Olson J J,et al.Proteomic identification of biomarkers in the cerebrospinal fluid(CSF) of astrocytoma patients[J].J Proteome Res,2007,6 (2):559-570.
[16]Ribom D,Westman-Brinkmalm A,Smits A,et al.Elevated levels of alpha-2-Here-mans-Schmid glycoprotein in CSF of patients with low-grade gliomas[J]. Tumor Biol,2003,24(2):94-99.
[17]Zhang H, Wu G,Tu H,et al.Discovery of serum biomarkers in astrocytoma by S-ELDI-TOF-MS and proteinchip technology[J],2007,84(3):315-323.
[18]王雅杰,方芳,周亚莉,等.血清中胶质瘤疾病相关蛋白质的筛选.中国实验诊断学,2008,12(5)：619-624.
[19]Zhang R, Tremblay TL, McDermid A,et al. Identification of differentially expre-ssed proteins in human glioblastoma cell lines and tumors.Glia,2003 Aprl5;42 (2):194-208.
[20]Vogel TW,Zhuang Z,Li J,Okamoto H,et al.Proteins and protein pattern differen-ces between glioma cell lines and glioblastoma multiforme. Clin Cancer Res.20 05 May 15;11(10):3624-3632.
[21]Odreman F,Vindigni M,Gonzales ML, et al. Proteomic studies on low-and high-grade human brain astrocytomas.J Proteome Res.2005 May-Jun;4(3):698-708.
[22]Chumbalkar V C, Subhashini C, Dhople V M, et al.Differential protein expressi-on in human gliomas and molecular insights[J].Proteomics,2005,5(4):1167-117 7.
[23]Zhang H, Wu G, Tu H, et al. Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology.J Neurooncol.2007 Sep;84(3):315-323.
[24]Vogel T W,Zhuang Z,Li J,et al.Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme[J].Clin Cancer Res,2005,11(10): 3624-3632.
[25]Goplen D,Wang J,Enger P, et al.Protein disulfide isomerase expression is related to the invasive properties of malignant glioma[J].Cancer Res,2006,66(20):9895-9902.
[26]Beckner M E,Chen X, An J,et al.Proteomic characterization of harvested pseud-opodia with differential gel electrophoresis and specific antibodies[J].Lab Inve-st,2005,85(3):316-327.
[27]Hiratsuka M,Inoue T,Toda T,et al.Proteomics-based identification of differentia-lly expressed genes in human gliomas:down-regulation of SIRT2 gene.Bioche-m Biophys Res Commun.2003 Sep 26;309(3):558-566.
[28]Park C K, Kim J H, Moon M J, et al. Investigation of molecular factors associa-ted with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression[J].J Cancer Res Clin Oncol,2008,134 (2):255-262.
[29]Okamoto H,Li J,Glasker S,et al.Proteomic comparison of oligodendrogliomas with and without 1pLOH[J].2007,6(3):391-396.
[30]Demasi M A,Montor W R,Ferreira G B,et al.Differential proteomic analysis of the anti-proliferative effect of glucocorticoid hormones in ST1 rat glioma cells [J].J Steroid Biochem Mol Biol,2007,103(2):137-148.
[31]Iwadate Y, Sakaida T,Saegusa T,et al.Proteome-based identification of molecul-ar markers predicting chemosensitivity to each category of anticancer agents in human gliomas[J].Int J Oncol.2005,26 (4):993-998.
[32]Trog D,Fountoulakis M,Friedlein A,et al.Is current therapy of malignant glioma-s beneficial for patients?Proteomics evidence of shifts in glioma cells expressi-on patterns under clinically relevant treatment conditions[J].Proteomics,2006,6 (9):2924-2930.
[33]Puchades M,Nilsson C L, Emmett M R,et al.Proteomic investigation of gliobas-toma cell lines treated with wild-type p53 and cytotoxic chemotherapy demons-trates an association between galectin-1 and p53 expression[J].J Proteome Res, 2007,6(2):869-875.
[34]Furnari FB,Fenton T,Bachoo RM,et al.Malignant astrocytic glioma:genetics, biology,and paths to treatment.Genes Dev,2007,21(21):2683-2710.
[35]陈自强,卞修武,辛榕,等.人脑胶质瘤细胞系CHG-5的建立及其生物学特性的分析.第三军医大学学报,1999,21(12)：880-883.
[36]王淑兰,李峰,浦佩玉,等,人脑恶性胶质母细胞瘤体外细胞系TJ899及TJ905的建立及其特征.天津医药,1996(7)：33-35.
[37]Brommeland T,Rosengren L,Fridlund S,et al.Serum levels of glial fibrillary aci-dic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Sca-nd,2007,116(6):380-384.
[38]Horst M,Brouwer E,Verwijnen S,et al.Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med, 2007,9(12):1071-1079.
[39]张锟,王雅杰,刘晓谦等.胶质瘤GFAP、S-100、Vimentin的表达及其与肿瘤恶性程度关系的研究.中华现代临床医学杂志.2003,11(1)：78-80.
[40]张锟,王雅杰,刘晓谦.胶质瘤GFAP、S-100、Vimentin的表达及其与肿瘤恶性程度关系的研究.中华现代临床医学杂志,2003,1(11)：967-969.
[41]康春生,浦佩玉,王广秀.反义AKT2 RNA逆转C6胶质瘤的细胞恶性表型.中华实验外科杂志,2005,22(7)：852-854.
[42]Harada T,Morooka T,Ogawa S,et al.ERK1/2 induces p35,a neuron-specific acti-vator of Cdk5,through induction of Egrl.Nature Cell Biology,2001,3:453-459.
[43]Uht RM, Amos S, Martin PM,et al.The protein kinase C-eta isoform induces pr-oliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene, 2007,26(20):2885-2893.
[44]Zolota V,Tsamandas AC,Aroukatos P, et al.Expression of cell cycle inhibitors p21,p27, p14 and p16 in gliomas:Correlation with classic prognostic factors and patients'outcome. Neuropathology,2008,28(1):35-42.
[45]刘奕生,刘慕嫦,张惠球,等.p53、ras基因产物在胶质瘤中的表达与肿瘤分级的关系.实验肿瘤学杂志,2005,19(2)：111-113.
[46]黄宽明,冯艳琴,张力,等.冷冻治疗对大鼠C6脑胶质瘤细胞凋亡和p21表达的影响.中国临床神经外科杂志,2006,11(4)：222-225.
[47]王占祥,章翔,费舟,等.外源性p21WAF1/CIP1基因转染对人胶质瘤细胞生长和细胞周期的影响.第四军医大学学报,2003,24(22)：2030-2033.
[48]王占祥,章翔,易声禹,等.脑胶质瘤组织p21WAF1/CIP1基因表达与p53基因的关系.第四军医大学学报,2000,21(9)：1102-1104.
[49]刘玉胜,鹿庆华,蒋卫东.组织蛋白酶与细胞外基质重塑.基础医学与临床, 2006,26(9)：037-1040.
[50]刘刚,陈谦学,吴立权,等.整合素β3和组织蛋白酶D在人脑胶质瘤中的表达及意义.中华临床神经外科杂志,2006,11(1)：27-28.
[51]周静,刘新光,梁念慈.蛋白激酶CK2与补体系统.国际检验医学杂志,2006,27(5)：432-434.
[52]Leirdal M,Sioud M.Ribozyme inhibition of the protein Kinase C alpha triggers apoptosis in glioma cells.Br J Canner,1999,80(10):1558-1564.
[53]Assert R,Kotter R,Bisping G,et al.Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts:evidence for a less activated p-rotein kinase C in small adenomas.Int J Cancer,1999,80(1):47-53.
[54]刘浩,廖达光,张天一,等.PKCa、PCNA、GFAP、EGFR在脑胶质瘤中的表达及临床意义.中国现代外科学杂志,2005,2(20)：1837-1839.
[55]周彬,邓艳春,刘新平,等.胶质瘤中NDRG2,PKCa mRNA表达及相关性研究.第四军医大学学报,2008,29(9)：782-784.
[56]Harrington EO,Loffer J,Nelson PR,et al.Enhancement of migration by protein kinase C alpha and inhibition of proliferation and cell cycle progression by pro-tein kinase C detta in capillary and othelial cells.J Biol Chm,1997,272(11):739 0-7397.
[57]王存祖,傅震,赵竹青.胶质瘤中PKCa表达及与细胞增殖和凋亡的关系.中华神外科疾病研究杂志,2004,3(1)：16-19.
[1]王忠诚.王忠诚神经外科学[M].湖北科技出版社,2005：212-218.
[2]Patterson S D,Aebersold R H.Proteomies:the first decade and beyond.Nat Genet, 2003,(Supp1):311-323.
[3]Yuan X,Desiderio D M.Proteomics analysis of human cerebrospinal fluid. J Chro-matogr B,2005,815:179-189.
[4]黄河,任惠民.神经系统重大疾病中蛋白质组学的应用.中国临床神经科学,2007,15(2)：189-194.
[5]Thongboonkerd V.Proteomics.Forum Nutr,2007,60:80-90.
[6]Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophore-sis and mass spectrometry:Strengths and limitations.Trac-Trends Anal Chem,20 03,5:273-281.
[7]Andrade E C, Krueger D D,Nairn A C. Recent advances in neuroproteomics.Curr Opin Mol Ther,2007,9:270-281.
[8]Schuhmann M U,Heine G,Skardelly M,et al.Brain injury and proteomics/peptide-mics:is it relevant? an overview. Acta Neurochir Suppl,2005,95(4):465-470.
[9]Luckl J,Farkas O,Pal J,et al.Protein biomarkers in experimental models and in cl-inical care of traumatic brain injury. Ideggyogy Sz,2007,60(7):284-294.
[10]Yang S,Huang C M.Recent advances in protein profiling of tissues and tissue fl-uids. Expert Rev Proteomics,2007,4(4):515-529.
[11]Bicknese A R,Goodwin H S,Quinn C O,et al.Human umbilica cord blood cells can be induced to express markers for neurons and glia.Cell Transplant,2002,11: 261-264.
[12]Zhang R,Tremblay T L, McDermid A,et al.Identification of differentially expre-ssed proteins in human glioblastoma cell lines and tumors.Glia.2003 Apr15;42 (2):194-208.
[13]Hiratsuka M,Inoue T, Toda T,et al. Proteomics-based identification of different-ially expressed genes in human gliomas:down-regulation of SIRT2 gene.Bioch-em Biophys Res Commun.2003 Sep 26;309(3):558-566.
[14]Iwadate Y, Sakaida T, Hiwasa T,et al.Molecular classification and survival pre- diction in human gliomas based on proteome analysis.Cancer Res.2004 Apr 1;64(7):2496-2501.
[15]Schwartz S A,Weil R J,Johns on M D,et al.Protein profiling in brain tumors us-ing mass spectrometry:feasibility of a new technique for the analysis of protein expression.Clin Cancer Res,2004,10:981-987.
[16]Vogel T W, Zhuang Z,Li J,Okamoto H,et al.Proteins and protein pattern differe-nces between glioma cell lines and glioblastoma multiforme.Clin Cancer Res.2 005 May 15:11(10):3624-3632.
[17]Odreman F,Vindigni M,Gonzales M L,et al.Proteomic studies on low and high-grade human brain astrocytomas.J Proteome Res.2005 May-Jun;4(3):698-708.
[18]Chumbalkar V C,Subhashini C,Dhople V M,et al.Differential protein expression in human gliomas and molecular insights[J].Proteomics,2005,5(4):1167-1177.
[19]Beckner M E,Chen X,An J,et al.Proteomic characterization of harvested pseud-opodia with differential gel electrophoresis and specific antibodies[J].Lab Inve-st,2005,85(3):316-327.
[20]Vogel T W,Zhuang Z, Li J,et al.Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme[J].Clin Cancer Res,2005,11(10): 3624-3632.
[21]Odreman F,Vindigni M,Gonzales M L,et al.Proteomic studies on low-and high-grade human brain astrocytomas[J].J Proteome Res.2005.4(3):698-708.
[22]Mennel H D,Hallier-Neelsen M,Hagner S,et al.Two novel cell specific receptor proteins, CRLR and CD117 in human glial tumors[J].Clin Neuropathol,2006, 25(3):107-114.
[23]Zhou L,Wang Y,Zhang Y T,et al.Proteomics-based analysis of a pair of glioma cell lines with different tumor forming characteristics[J].Neurosci Lett,2006,40 1(2):59-64.
[24]Goplen D,Wang J,Enger P,et al.Protein disulfide isomerase expression is related to the invasive properties of malignant glioma[J].Cancer Res.2006,66(20):9895 9902.
[25]Shim J H, Kim Y S, Bahk Y Y. Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells[J]. Proteomics,2006, 6(1):81-93.
[26]Zhang H, Wu G,Tu H,et al.Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology.J Neurooncol.2007Sep;84(3):315-323.
[27]Khalil A A.Biomarker discovery:a proteomic approach for brain cancer proflili-ng.Cancer Sci.2007 Feb;98(2):201-213.
[28]阚慕洁,迟秀梅,李奇,等.海洛因对大鼠C6胶质瘤细胞的双向电泳图谱比较.中国实验诊断学,2007,11(8)：1008-1010.
[29]Park C K, Kim J H, Moon M J, et al. Investigation of molecular factors associa-ted with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression [J].J Cancer Res Clin Oncol,2008,134 (2):255-262.
[30]Ribom D,Westman-Brinkmalm A, Smits A,et al.Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas[J]. Tumour Biol,2003,24(2):94-99.
[31]Zheng P P,Luider T M,Pieters R,et al.Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors[J].J Neuropathol Exp Neurol,2003,62 (8);855-862.
[32]刘建,郑树,余捷凯,等.胶质瘤脑脊液蛋白指纹图质谱仪分析及其在临床诊断中的应用.中华神经外科杂志,2004,20(5)：362-366.
[33]Khwaja F W, Reed M S,Olson J J,et al.Proteomic identification of biomarkers in the cerebrospinal fluid(CSF) of astrocytoma patients [J]. J Proteome Res,200 7,6(2):559-570.
[34]Zhang H,Wu G,Tu H,et al.Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology [J],2007,84(3):315-323.
[35]王雅杰,方芳,周亚莉,等.血清中胶质瘤疾病相关蛋白质的筛选.中国实验诊断学,2008,12(5)：619-624.
[36]Schmaier A H,McCrae K R.The plasma kallikrein-kinin system:its evolution from contact activation[J].Thromb Haemost,2007,5(12):2323.
[2]Washinger C V,Cord well S J, Cerpa-poljak A,et al.Progress with gene-product mapping of the Mollicutes:Mycoplasma genitalium[J], Electrophoresis,1995,16 (7):1090-1094.
[3]Abbott A:Apost-genomic challenge:learning to read patterns of protein synthesis. Nature 1999,402:715-720.
[4]Fields S,Proteomics on genomeland.Science,2001,291(5507):1221-1224.
[5]Patterson S D, Aebersold R H. Proteomies:the first decade and beyond. Nat Gen-et,2003,(Supp1):311-323.
[6]Gorg A,Obermaier C,Boguth G,et al.The current state of two-dimensional electrop-horesis with immobilized pH gradients.Electrophoresis,2000,21:1037-1053.
[7]O,Farrell PH.High resolution two-dimensional electrophoresis of protein [J]. J Boil Chem,1975,250(10):4007-4021.
[8]Thongboonkerd V. Proteomics.Forum Nutr,2007,60:80-90.
[9]Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophore-sis and mass spectrometry:Strengths and limitations.Trac-Trends Anal Chem,200 3,5:273-281.
[10]王忠诚.王忠诚神经外科学[M].湖北科技出版社,2005：212-218.
[11]Bicknese A R,Goodwin H S, Quinn C O, et al.Human umbilica cord blood cells can be induced to express markers for neurons and glia.Cell Transplant,2002,11: 261-264.
[12]Odreman F,Vindigni M,Gonzales M L,et al.Proteomic studies on low-and high-grade human brain astrocytomas[J].J Proteome Res,2005,4(3):698-708.
[13]Mennel HD, Hallier-Neelsen M, Hagner S, et al. Two novel cell specific recept-or proteins,CRLR and CD117 in human glial tumors [J].Clin Neuropathol,2006, 25(3):107-114.
[14]Zheng P P,Luider T M, Pieters R,et al.Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain turn- ors[J].J Neuropathol Exp Neurol,2003,62(8):855-862.
[15]Khwaja F W,Reed M S,Olson J J,et al.Proteomic identification of biomarkers in the cerebrospinal fluid(CSF) of astrocytoma patients[J].J Proteome Res,2007,6 (2):559-570.
[16]Ribom D,Westman-Brinkmalm A,Smits A,et al.Elevated levels of alpha-2-Here-mans-Schmid glycoprotein in CSF of patients with low-grade gliomas[J]. Tumor Biol,2003,24(2):94-99.
[17]Zhang H, Wu G,Tu H,et al.Discovery of serum biomarkers in astrocytoma by S-ELDI-TOF-MS and proteinchip technology[J],2007,84(3):315-323.
[18]王雅杰,方芳,周亚莉,等.血清中胶质瘤疾病相关蛋白质的筛选.中国实验诊断学,2008,12(5)：619-624.
[19]Zhang R, Tremblay TL, McDermid A,et al. Identification of differentially expre-ssed proteins in human glioblastoma cell lines and tumors.Glia,2003 Aprl5;42 (2):194-208.
[20]Vogel TW,Zhuang Z,Li J,Okamoto H,et al.Proteins and protein pattern differen-ces between glioma cell lines and glioblastoma multiforme. Clin Cancer Res.20 05 May 15;11(10):3624-3632.
[21]Odreman F,Vindigni M,Gonzales ML, et al. Proteomic studies on low-and high-grade human brain astrocytomas.J Proteome Res.2005 May-Jun;4(3):698-708.
[22]Chumbalkar V C, Subhashini C, Dhople V M, et al.Differential protein expressi-on in human gliomas and molecular insights[J].Proteomics,2005,5(4):1167-117 7.
[23]Zhang H, Wu G, Tu H, et al. Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology.J Neurooncol.2007 Sep;84(3):315-323.
[24]Vogel T W,Zhuang Z,Li J,et al.Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme[J].Clin Cancer Res,2005,11(10): 3624-3632.
[25]Goplen D,Wang J,Enger P, et al.Protein disulfide isomerase expression is related to the invasive properties of malignant glioma[J].Cancer Res,2006,66(20):9895-9902.
[26]Beckner M E,Chen X, An J,et al.Proteomic characterization of harvested pseud-opodia with differential gel electrophoresis and specific antibodies[J].Lab Inve-st,2005,85(3):316-327.
[27]Hiratsuka M,Inoue T,Toda T,et al.Proteomics-based identification of differentia-lly expressed genes in human gliomas:down-regulation of SIRT2 gene.Bioche-m Biophys Res Commun.2003 Sep 26;309(3):558-566.
[28]Park C K, Kim J H, Moon M J, et al. Investigation of molecular factors associa-ted with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression[J].J Cancer Res Clin Oncol,2008,134 (2):255-262.
[29]Okamoto H,Li J,Glasker S,et al.Proteomic comparison of oligodendrogliomas with and without 1pLOH[J].2007,6(3):391-396.
[30]Demasi M A,Montor W R,Ferreira G B,et al.Differential proteomic analysis of the anti-proliferative effect of glucocorticoid hormones in ST1 rat glioma cells [J].J Steroid Biochem Mol Biol,2007,103(2):137-148.
[31]Iwadate Y, Sakaida T,Saegusa T,et al.Proteome-based identification of molecul-ar markers predicting chemosensitivity to each category of anticancer agents in human gliomas[J].Int J Oncol.2005,26 (4):993-998.
[32]Trog D,Fountoulakis M,Friedlein A,et al.Is current therapy of malignant glioma-s beneficial for patients?Proteomics evidence of shifts in glioma cells expressi-on patterns under clinically relevant treatment conditions[J].Proteomics,2006,6 (9):2924-2930.
[33]Puchades M,Nilsson C L, Emmett M R,et al.Proteomic investigation of gliobas-toma cell lines treated with wild-type p53 and cytotoxic chemotherapy demons-trates an association between galectin-1 and p53 expression[J].J Proteome Res, 2007,6(2):869-875.
[34]Furnari FB,Fenton T,Bachoo RM,et al.Malignant astrocytic glioma:genetics, biology,and paths to treatment.Genes Dev,2007,21(21):2683-2710.
[35]陈自强,卞修武,辛榕,等.人脑胶质瘤细胞系CHG-5的建立及其生物学特性的分析.第三军医大学学报,1999,21(12)：880-883.
[36]王淑兰,李峰,浦佩玉,等,人脑恶性胶质母细胞瘤体外细胞系TJ899及TJ905的建立及其特征.天津医药,1996(7)：33-35.
[37]Brommeland T,Rosengren L,Fridlund S,et al.Serum levels of glial fibrillary aci-dic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Sca-nd,2007,116(6):380-384.
[38]Horst M,Brouwer E,Verwijnen S,et al.Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med, 2007,9(12):1071-1079.
[39]张锟,王雅杰,刘晓谦等.胶质瘤GFAP、S-100、Vimentin的表达及其与肿瘤恶性程度关系的研究.中华现代临床医学杂志.2003,11(1)：78-80.
[40]张锟,王雅杰,刘晓谦.胶质瘤GFAP、S-100、Vimentin的表达及其与肿瘤恶性程度关系的研究.中华现代临床医学杂志,2003,1(11)：967-969.
[41]康春生,浦佩玉,王广秀.反义AKT2 RNA逆转C6胶质瘤的细胞恶性表型.中华实验外科杂志,2005,22(7)：852-854.
[42]Harada T,Morooka T,Ogawa S,et al.ERK1/2 induces p35,a neuron-specific acti-vator of Cdk5,through induction of Egrl.Nature Cell Biology,2001,3:453-459.
[43]Uht RM, Amos S, Martin PM,et al.The protein kinase C-eta isoform induces pr-oliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene, 2007,26(20):2885-2893.
[44]Zolota V,Tsamandas AC,Aroukatos P, et al.Expression of cell cycle inhibitors p21,p27, p14 and p16 in gliomas:Correlation with classic prognostic factors and patients'outcome. Neuropathology,2008,28(1):35-42.
[45]刘奕生,刘慕嫦,张惠球,等.p53、ras基因产物在胶质瘤中的表达与肿瘤分级的关系.实验肿瘤学杂志,2005,19(2)：111-113.
[46]黄宽明,冯艳琴,张力,等.冷冻治疗对大鼠C6脑胶质瘤细胞凋亡和p21表达的影响.中国临床神经外科杂志,2006,11(4)：222-225.
[47]王占祥,章翔,费舟,等.外源性p21WAF1/CIP1基因转染对人胶质瘤细胞生长和细胞周期的影响.第四军医大学学报,2003,24(22)：2030-2033.
[48]王占祥,章翔,易声禹,等.脑胶质瘤组织p21WAF1/CIP1基因表达与p53基因的关系.第四军医大学学报,2000,21(9)：1102-1104.
[49]刘玉胜,鹿庆华,蒋卫东.组织蛋白酶与细胞外基质重塑.基础医学与临床, 2006,26(9)：037-1040.
[50]刘刚,陈谦学,吴立权,等.整合素β3和组织蛋白酶D在人脑胶质瘤中的表达及意义.中华临床神经外科杂志,2006,11(1)：27-28.
[51]周静,刘新光,梁念慈.蛋白激酶CK2与补体系统.国际检验医学杂志,2006,27(5)：432-434.
[52]Leirdal M,Sioud M.Ribozyme inhibition of the protein Kinase C alpha triggers apoptosis in glioma cells.Br J Canner,1999,80(10):1558-1564.
[53]Assert R,Kotter R,Bisping G,et al.Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts:evidence for a less activated p-rotein kinase C in small adenomas.Int J Cancer,1999,80(1):47-53.
[54]刘浩,廖达光,张天一,等.PKCa、PCNA、GFAP、EGFR在脑胶质瘤中的表达及临床意义.中国现代外科学杂志,2005,2(20)：1837-1839.
[55]周彬,邓艳春,刘新平,等.胶质瘤中NDRG2,PKCa mRNA表达及相关性研究.第四军医大学学报,2008,29(9)：782-784.
[56]Harrington EO,Loffer J,Nelson PR,et al.Enhancement of migration by protein kinase C alpha and inhibition of proliferation and cell cycle progression by pro-tein kinase C detta in capillary and othelial cells.J Biol Chm,1997,272(11):739 0-7397.
[57]王存祖,傅震,赵竹青.胶质瘤中PKCa表达及与细胞增殖和凋亡的关系.中华神外科疾病研究杂志,2004,3(1)：16-19.
[1]王忠诚.王忠诚神经外科学[M].湖北科技出版社,2005：212-218.
[2]Patterson S D,Aebersold R H.Proteomies:the first decade and beyond.Nat Genet, 2003,(Supp1):311-323.
[3]Yuan X,Desiderio D M.Proteomics analysis of human cerebrospinal fluid. J Chro-matogr B,2005,815:179-189.
[4]黄河,任惠民.神经系统重大疾病中蛋白质组学的应用.中国临床神经科学,2007,15(2)：189-194.
[5]Thongboonkerd V.Proteomics.Forum Nutr,2007,60:80-90.
[6]Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophore-sis and mass spectrometry:Strengths and limitations.Trac-Trends Anal Chem,20 03,5:273-281.
[7]Andrade E C, Krueger D D,Nairn A C. Recent advances in neuroproteomics.Curr Opin Mol Ther,2007,9:270-281.
[8]Schuhmann M U,Heine G,Skardelly M,et al.Brain injury and proteomics/peptide-mics:is it relevant? an overview. Acta Neurochir Suppl,2005,95(4):465-470.
[9]Luckl J,Farkas O,Pal J,et al.Protein biomarkers in experimental models and in cl-inical care of traumatic brain injury. Ideggyogy Sz,2007,60(7):284-294.
[10]Yang S,Huang C M.Recent advances in protein profiling of tissues and tissue fl-uids. Expert Rev Proteomics,2007,4(4):515-529.
[11]Bicknese A R,Goodwin H S,Quinn C O,et al.Human umbilica cord blood cells can be induced to express markers for neurons and glia.Cell Transplant,2002,11: 261-264.
[12]Zhang R,Tremblay T L, McDermid A,et al.Identification of differentially expre-ssed proteins in human glioblastoma cell lines and tumors.Glia.2003 Apr15;42 (2):194-208.
[13]Hiratsuka M,Inoue T, Toda T,et al. Proteomics-based identification of different-ially expressed genes in human gliomas:down-regulation of SIRT2 gene.Bioch-em Biophys Res Commun.2003 Sep 26;309(3):558-566.
[14]Iwadate Y, Sakaida T, Hiwasa T,et al.Molecular classification and survival pre- diction in human gliomas based on proteome analysis.Cancer Res.2004 Apr 1;64(7):2496-2501.
[15]Schwartz S A,Weil R J,Johns on M D,et al.Protein profiling in brain tumors us-ing mass spectrometry:feasibility of a new technique for the analysis of protein expression.Clin Cancer Res,2004,10:981-987.
[16]Vogel T W, Zhuang Z,Li J,Okamoto H,et al.Proteins and protein pattern differe-nces between glioma cell lines and glioblastoma multiforme.Clin Cancer Res.2 005 May 15:11(10):3624-3632.
[17]Odreman F,Vindigni M,Gonzales M L,et al.Proteomic studies on low and high-grade human brain astrocytomas.J Proteome Res.2005 May-Jun;4(3):698-708.
[18]Chumbalkar V C,Subhashini C,Dhople V M,et al.Differential protein expression in human gliomas and molecular insights[J].Proteomics,2005,5(4):1167-1177.
[19]Beckner M E,Chen X,An J,et al.Proteomic characterization of harvested pseud-opodia with differential gel electrophoresis and specific antibodies[J].Lab Inve-st,2005,85(3):316-327.
[20]Vogel T W,Zhuang Z, Li J,et al.Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme[J].Clin Cancer Res,2005,11(10): 3624-3632.
[21]Odreman F,Vindigni M,Gonzales M L,et al.Proteomic studies on low-and high-grade human brain astrocytomas[J].J Proteome Res.2005.4(3):698-708.
[22]Mennel H D,Hallier-Neelsen M,Hagner S,et al.Two novel cell specific receptor proteins, CRLR and CD117 in human glial tumors[J].Clin Neuropathol,2006, 25(3):107-114.
[23]Zhou L,Wang Y,Zhang Y T,et al.Proteomics-based analysis of a pair of glioma cell lines with different tumor forming characteristics[J].Neurosci Lett,2006,40 1(2):59-64.
[24]Goplen D,Wang J,Enger P,et al.Protein disulfide isomerase expression is related to the invasive properties of malignant glioma[J].Cancer Res.2006,66(20):9895 9902.
[25]Shim J H, Kim Y S, Bahk Y Y. Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells[J]. Proteomics,2006, 6(1):81-93.
[26]Zhang H, Wu G,Tu H,et al.Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology.J Neurooncol.2007Sep;84(3):315-323.
[27]Khalil A A.Biomarker discovery:a proteomic approach for brain cancer proflili-ng.Cancer Sci.2007 Feb;98(2):201-213.
[28]阚慕洁,迟秀梅,李奇,等.海洛因对大鼠C6胶质瘤细胞的双向电泳图谱比较.中国实验诊断学,2007,11(8)：1008-1010.
[29]Park C K, Kim J H, Moon M J, et al. Investigation of molecular factors associa-ted with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression [J].J Cancer Res Clin Oncol,2008,134 (2):255-262.
[30]Ribom D,Westman-Brinkmalm A, Smits A,et al.Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas[J]. Tumour Biol,2003,24(2):94-99.
[31]Zheng P P,Luider T M,Pieters R,et al.Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors[J].J Neuropathol Exp Neurol,2003,62 (8);855-862.
[32]刘建,郑树,余捷凯,等.胶质瘤脑脊液蛋白指纹图质谱仪分析及其在临床诊断中的应用.中华神经外科杂志,2004,20(5)：362-366.
[33]Khwaja F W, Reed M S,Olson J J,et al.Proteomic identification of biomarkers in the cerebrospinal fluid(CSF) of astrocytoma patients [J]. J Proteome Res,200 7,6(2):559-570.
[34]Zhang H,Wu G,Tu H,et al.Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology [J],2007,84(3):315-323.
[35]王雅杰,方芳,周亚莉,等.血清中胶质瘤疾病相关蛋白质的筛选.中国实验诊断学,2008,12(5)：619-624.
[36]Schmaier A H,McCrae K R.The plasma kallikrein-kinin system:its evolution from contact activation[J].Thromb Haemost,2007,5(12):2323.